PTMA may protect T-cells during lymphopenia in COVID-19 and the administration of thymosin alpha- 1(Tα1), final product of PTMA, is suggested as a potential approach to protect effector T-cells during COVID-19 [61]. Here, PTMA is linked to lymphopenia.